We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

By LabMedica International staff writers
Posted on 10 May 2021
To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such as that caused by COVID-19, a team of researchers at Queen Mary University of London (United Kingdom) developed a novel smell testing kit based on capsules of aromatic oils placed between two strips of single-sided tape.

This smelling test was made up of aromatic oil capsules that were prepared by a fabrication technique, which enabled full control over the capsule size, the shell thickness, and the volume of the encapsulated oil. More...
The technique generated capsules by concentrically dripping oil/alginate droplets from a coaxial nozzle into an oppositely charged ionic liquid. After formation, liquid capsules were left to dry and form a solid crust surrounding the oil.

The prototype test used in the current study consisted of placing a standardized number of capsules between adhesive strips that users crushed and pulled apart to release the smell. In addition, a simple mathematical model was developed to predict the volume of encapsulated oil within the capsule in terms of the flow rate ratio and the nozzle size.

In this preliminary study, a small group of eight patients with Parkinson's disease were instructed to crush the capsules between their fingers and then peel back the tape strip to release the aroma contained within the capsules.

The participants reported that the smells from the tests were detectable and remarked on the relative ease of rupturing the capsules, particularly for those with tremors, compared to the standard scratch and sniff smell test available on the market.

First author Dr. Ahmed Ismail, a lecturer of fluid dynamics at Queen Mary University of London, said, "Most of the smell tests on the market depend on using paperboard items treated with a fragrant coating called scratch and sniff, in which you need to scratch a card to release the odor. The problem with this approach is that the amount of odor released depends on the extent to which the individual scratches, something that might affect the outcome of the test. Our capsule-based smell test does not have this problem because the amount of odor released is controlled by the amount of oil precisely encapsulated. The mass-production of our new test would also be cheaper than a scratch and sniff test.

Dr. Ismail said, "Our capsule-based smell test can assist in the rapid diagnostic of various diseases linked to the loss of smell. These include chronic neurological conditions such as Parkinson's and Alzheimer's disease, as well as COVID-19, which is known to affect the sense of smell. Being non-invasive and less stressful, the capsule-based smell test has benefits over the nose swab in diagnosing COVID-19. This is an advantage for testing children in particular, as they are typically horrified if they need to do a nose swab, and the test can be done in the comfort of their own home."

The capsule-based smell test was described in the April 28, 2021, online edition of the journal Royal Society Interface.

Related Links:
Queen Mary University of London


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple oral swab detected blood-matched inflammatory signals in children with primary ciliary dyskinesia, offering a needle-free way to monitor inflammation during routine care (Image credit: Shutterstock)

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.